Erbitux Oncologic Potential Endorsed By FDA, Bristol During House Hearing

ImClone's oncologic agent Erbitux is "an active anticancer agent," Bristol-Myers Squibb and FDA Oncologic Drug Products Division Director Richard Pazdur, MD, agreed during a June 13 Energy & Commerce/Oversight Subcommittee hearing